Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a private placement, raising $4.25 million to support its operations and potential acquisitions [1][2]. Group 1: Financial Details - The company issued 1,180,877 shares of common stock at a purchase price of $3.60 per share, in accordance with Nasdaq rules [2]. - The gross proceeds from the offering amount to $4.25 million, which will be utilized for acquisitions, marketing, and general corporate purposes [1]. Group 2: Company Overview - Shuttle Pharmaceuticals is focused on enhancing outcomes for cancer patients undergoing radiation therapy by developing therapies that maximize the effectiveness of radiation while minimizing side effects [6]. - The company's mission includes increasing cancer cure rates, prolonging patient survival, and improving quality of life through the development of radiation sensitizers [6].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of 19,166,667 shares at a price of $0.30 per share, aiming to raise approximately $5.75 million to fund its Phase II clinical trial and other corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $0.30 per share, with expected gross proceeds of about $5.75 million before expenses [1]. - The offering is set to close on March 13, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund the Phase II clinical trial for the lead product candidate, marketing and advertising services, and general corporate purposes [2]. Group 3: Company Overview - Shuttle Pharmaceuticals, founded in 2012, focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [5]. - The company aims to increase cancer cure rates and improve patient quality of life through the development of radiation sensitizers [5].